



Volume 1, Issue 10
November 2022

Pharmacy Benefits Management- Medical Advisory Panel- VISN Pharmacist Executives E_z - MINUTES

Drugs Added to the VA National Formulary WITHOUT Prior Authorization

- Fexofenadine tablet

Drugs Added to the VA National Formulary WITH Prior Authorization

- Nitroglycerin Rectal Ointment 0.4% (RECTIV)
- Abemaciclib (VERZENIO)
- Ribociclib (KISQALI)
- Tucatinib (TUKYSA)
- Sodium Phenylbutyrate/Taurursodiol (PB-TURSO, RELYVRIO®)

Drugs Not Added to the VA National Formulary

- Varenicline nasal spray (TYRVAYA)
- Triamcinolone Acetonide Extended-Release (ZILRETTA) Inj. Susp.
- Levocetirizine tablet
- Bevacizumab-maly (ALYMSYS) Biosimilar
- Pegfilgrastim-pbbk (FYLNETRA) Biosimilar
- Dextromethorphan and Bupropion Extended-Release Tablets AUVELITY
- Triliciclib (COSELA)

Formulary Drugs with Prior Authorization Removed

- none

Drugs Removed from the VA National Formulary

- Bethanechol Inj
- Cromolyn Cap
- Delavirdine Tab
- Edrophonium Inj
- Fluoxymesterone Tab
- Indinavir Cap
- Isoniazid/Rifampin Cap
- Mechlorethamine Inj
- Nandrolone Decanoate Inj
- Peg-Interferon Alfa-2b Inj
- Propantheline Bromide Tab
- Saquinavir Cap
- Theophylline IR Tab
- Theophylline IR Cap

Other Announcements

- Ivabradine (CORLANOR) CFU revision
- Tocilizumab (ACTEMRA) in Giant Cell Arteritis CFU revision
- Tocilizumab (ACTEMRA) in Rheumatoid Arthritis CFU revision
- Dupilumab (DUPIXENT) in Eosinophilic Esophagitis (EoE) Monograph Addendum and CFU
- Testosterone injection, patch, and gel now PA-F
- Edaravone IV and oral solution, now PA-N